Lilly Japan To Enlarge Domestic Market Share With New Indications
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan KK plans to increase sales in Japan by seeking new indications for its existing pipeline of drugs. The subsidiary of U.S.-based Eli Lilly, the company began the program by filing for Japanese approval of Gemzar (gemcitabine), a non-small cell lung cancer medicine, for treating biliary tract cancer, and its Cialis (tadalafil) erectile dysfunction drug for treating pulmonary hypertension. The firm says seven of the 13 drugs it has in development are new applications for already-approved products. All of the planning is to reach a goal of moving into the ranks of the top 15 pharmaceuticals in the country by 2025, up from its current 23rd place. (Click here for more - a subscription may be required